PMC:7228307 / 46330-46704
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 882 | 96-104 | Gene | denotes | FcγRIIIa | Gene:2214 |
| 883 | 201-205 | Gene | denotes | HER2 | Gene:2064 |
| 884 | 212-216 | Gene | denotes | EGFR | Gene:1956 |
| 885 | 358-365 | Gene | denotes | FcγRIII | Gene:2214 |
| 893 | 167-172 | Disease | denotes | tumor | MESH:D009369 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T79 | 167-172 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T807 | 96-98 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
| T808 | 304-305 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T809 | 358-360 | http://purl.obolibrary.org/obo/CLO_0052676 | denotes | Fc |
LitCovid-sample-Pubtator
| Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
|---|---|---|---|---|---|
| 882 | 96-104 | Gene | denotes | FcγRIIIa | Gene:2214 |
| 883 | 201-205 | Gene | denotes | HER2 | Gene:2064 |
| 884 | 212-216 | Gene | denotes | EGFR | Gene:1956 |
| 885 | 358-365 | Gene | denotes | FcγRIII | Gene:2214 |
| 893 | 167-172 | Disease | denotes | tumor | MESH:D009369 |
LitCovid-sample-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T270 | 0-374 | Sentence | denotes | Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding. |
LitCovid-sample-UniProt
| Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
|---|---|---|---|---|---|
| T582 | 226-230 | Protein | denotes | CD20 | https://www.uniprot.org/uniprot/Q3C2E2|https://www.uniprot.org/uniprot/Q13963|https://www.uniprot.org/uniprot/P19437|https://www.uniprot.org/uniprot/P11836|https://www.uniprot.org/uniprot/P08984|https://www.uniprot.org/uniprot/B4DT24|https://www.uniprot.org/uniprot/A6NMS4 |
LitCovid-sample-PD-GO-BP-0
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T107 | 212-216 | http://purl.obolibrary.org/obo/GO_0005006 | denotes | EGFR |
LitCovid-sample-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T35 | 167-172 | Disease | denotes | tumor | http://purl.obolibrary.org/obo/MONDO_0005070 |
LitCovid-sample-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T31 | 167-172 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |
LitCovid-sample-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T107 | 212-216 | http://purl.obolibrary.org/obo/GO_0005006 | denotes | EGFR |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T107 | 212-216 | http://purl.obolibrary.org/obo/GO_0005006 | denotes | EGFR |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T270 | 0-374 | Sentence | denotes | Furthermore, this glycoengineering increased binding affinity of the modified IgG1 mAb for both FcγRIIIa V158 and F158 allelotypes.86, 87, 88 Afucosyl versions of the tumor targeting mAbs such as anti‐HER2, anti‐EGFR and anti‐CD20 had greater antitumor effects and increased survival,68, 88, 89 which is a reflection of the greatly increased, and selective, FcγRIII binding. |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T31 | 167-172 | Phenotype | denotes | tumor | http://purl.obolibrary.org/obo/HP_0002664 |